Newsroom

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each share of Amicus that they own. KSF is seeking to determine whether this consideration and the process...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have December 30, 2025 to file lead plaintiff applications in securities class action lawsuits against Synopsys, Inc. (“Synopsys” or the “Company”) (NasdaqGS: SNPS), if they purchased or otherwise acquired the Company’s securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”) and/o...

NORFOLK, Neb.--(BUSINESS WIRE)--Following the final charter approval of Telcoin Digital Asset Bank by the Nebraska Department of Banking and Finance last month, Telcoin begins initial blockchain banking operations today with the launch of its eUSD stablecoin on the Ethereum and Polygon blockchains. With the minting of $10 million eUSD, Telcoin’s flagship Digital Cash stablecoin is now live and one step closer to retail markets. “We’re thrilled to issue eUSD on Ethereum and Polygon as phase one...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming February 20, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Klarna Group plc (“Klarna” or the “Company”) (NYSE: KLAR) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company’s September 2025 initial public offering (the “IPO”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KL...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 29, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) common stock between March 5, 2024 and October 28, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVANTOR, INC. (AVTR), CLICK HERE TO PARTICIPATE IN THE SECURITIES F...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming February 17, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired F5, Inc. (“F5” or the “Company”) (NASDAQ: FFIV) securities between October 28, 2024 and October 27, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR F5 INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LO...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired SLM Corporation a/k/a Sallie Mae (“SLM” or the “Company”) (NASDAQ: SLM) securities between July 25, 2025 and August 14, 2025, inclusive (the “Class Period”). SLM investors have until February 17, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Charming Medical Limited (“Charming” or the “Company”) (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025, inclusive (the “Class Period”). Charming investors have until February 17, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A...

DUBLIN--(BUSINESS WIRE)--The "Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)" training has been added to ResearchAndMarkets.com's offering. The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the diffe...

DUBLIN--(BUSINESS WIRE)--The "Navigating EU (European Union) and FDA (Food and Drug Administration) Regulations for Drug/Device and Device/Drug Combination Products Training Course (Mar 2nd - Mar 3rd, 2026)" training has been added to ResearchAndMarkets.com's offering. Understand the regulatory frameworks governing drug/device and device/drug combinations in the European Union and the USA. The demarcation between medicinal products and devices is becoming ever more important and, with the conve...